- Home
- TARA vs MRBK Comparison
TARA vs MRBK Comparison
Compare TARA & MRBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TARA | MRBK |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.5M | 218.1M |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | TARA | MRBK |
|---|---|---|
| Price | $5.71 | $18.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $21.86 | $20.00 |
| AVG Volume (30 Days) | ★ 1.1M | 72.8K |
| Earning Date | 06-18-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 2.94% |
| EPS Growth | ★ 38.25 | 25.00 |
| EPS | N/A | ★ 1.28 |
| Revenue | $2,948,000.00 | ★ $5,735,000.00 |
| Revenue This Year | N/A | $25.40 |
| Revenue Next Year | N/A | $8.15 |
| P/E Ratio | ★ N/A | $14.90 |
| Revenue Growth | N/A | ★ 16.38 |
| 52 Week Low | $2.77 | $11.17 |
| 52 Week High | $7.82 | $21.03 |
Technical Indicators
Market Signals| Indicator | TARA | MRBK |
|---|---|---|
| Relative Strength Index (RSI) | 43.53 | 43.28 |
| Support Level | $4.87 | $14.00 |
| Resistance Level | $5.77 | $19.24 |
| Average True Range (ATR) | 0.54 | 0.61 |
| MACD | -0.10 | -0.18 |
| Stochastic Oscillator | 17.27 | 31.54 |
Price Performance
Historical ComparisonAbout TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
About MRBK Meridian Corporation
Meridian Corp is a bank holding company. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal, business lending, and deposit services. It operates in three reportable segments including Bank, Wealth, and Mortgage. The company generates maximum revenue from the Bank segment which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans.